These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31619719)

  • 21. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
    Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
    Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Xu L; Che X; Wu Y; Song N; Shi S; Wang S; Li C; Zhang L; Zhang X; Qu X; Teng Y
    Oncol Rep; 2018 May; 39(5):2315-2323. PubMed ID: 29565454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.
    Zhang L; Wang XI; Zhang S
    Hum Pathol; 2018 Oct; 80():47-54. PubMed ID: 29883779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
    Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
    Ritter A; Hirschfeld M; Berner K; Rücker G; Jäger M; Weiss D; Medl M; Nöthling C; Gassner S; Asberger J; Erbes T
    Int J Oncol; 2020 Jan; 56(1):47-68. PubMed ID: 31789396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
    Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
    Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
    García-Vazquez R; Ruiz-García E; Meneses García A; Astudillo-de la Vega H; Lara-Medina F; Alvarado-Miranda A; Maldonado-Martínez H; González-Barrios JA; Campos-Parra AD; Rodríguez Cuevas S; Marchat LA; López-Camarillo C
    Tumour Biol; 2017 Jun; 39(6):1010428317702899. PubMed ID: 28621239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
    Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
    Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
    Balko JM; Giltnane JM; Wang K; Schwarz LJ; Young CD; Cook RS; Owens P; Sanders ME; Kuba MG; Sánchez V; Kurupi R; Moore PD; Pinto JA; Doimi FD; Gómez H; Horiuchi D; Goga A; Lehmann BD; Bauer JA; Pietenpol JA; Ross JS; Palmer GA; Yelensky R; Cronin M; Miller VA; Stephens PJ; Arteaga CL
    Cancer Discov; 2014 Feb; 4(2):232-45. PubMed ID: 24356096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive markers for pathological complete response after neo-adjuvant chemotherapy in triple-negative breast cancer.
    Van Bockstal MR; Noel F; Guiot Y; Duhoux FP; Mazzeo F; Van Marcke C; Fellah L; Ledoux B; Berlière M; Galant C
    Ann Diagn Pathol; 2020 Dec; 49():151634. PubMed ID: 32987254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
    Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Omar M; Nuzzo PV; Ravera F; Bleve S; Fanelli GN; Zanettini C; Valencia I; Marchionni L
    J Transl Med; 2023 Nov; 21(1):811. PubMed ID: 37964363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
    Wang RX; Chen S; Huang L; Shao ZM
    BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer.
    Narusawa E; Kurozumi S; Katayama A; Koibuchi Y; Ogawa A; Takata D; Tokuda S; Obayashi S; Oyama T; Horiguchi J; Shirabe K; Fujii T
    Med Mol Morphol; 2024 Sep; 57(3):177-184. PubMed ID: 38619618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
    Chen R; Ye Y; Yang C; Peng Y; Zong B; Qu F; Tang Z; Wang Y; Su X; Li H; Yang G; Liu S
    Breast Cancer Res Treat; 2018 Jul; 170(1):35-43. PubMed ID: 29480449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators.
    Zhang F; Huang M; Zhou H; Chen K; Jin J; Wu Y; Ying L; Ding X; Su D; Zou D
    Ann Surg Oncol; 2019 Nov; 26(12):3912-3919. PubMed ID: 31359285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.